Table 1.
Patient characteristics at baseline
| Characteristics | Paclitaxel (n = 38) | Paclitaxel+trametinib (n = 36) | Paclitaxel+pazopanib (n = 37) |
|---|---|---|---|
| Age, years, median (range) | 64 (35–80) | 60 (27–80) | 66 (41–80) |
| Gender male, n (%) | 27 (71) | 23 (64) | 25 (68) |
| Ethnicity, n (%) | |||
| White | 35 (92) | 33 (92) | 34 (92) |
| Other ethnic groups | 2 (5) | 2 (6) | 2 (5) |
| Not given | 1 (3) | 1 (3) | 1 (3) |
| ECOG performance score, n (%) | |||
| 0 | 21 (55) | 23 (64) | 25 (68) |
| 1 | 17 (45) | 13 (36) | 12 (32) |
| Disease stage at entry, n (%) | |||
| IV | 38 (100) | 34 (94) | 34 (92) |
| Unresectable stage III | 0 (0) | 2 (6) | 3 (8) |
| Stratification variables, n (%) | |||
| Prior therapy | 13 (34) | 12 (33) | 14 (38) |
| LDH within normal range | 19 (50) | 18 (50) | 18 (49) |
| NRAS mutant | 14 (37) | 14 (39) | 18 (49) |
n, number of patients in a group; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group.